Evaluating CD19 CAR expression levels in clinical trial and quality checks
High-Affinity CD19 for CAR-T Cell Therapy
Cancer immunotherapy with CAR-T cells – behold the future | RCP Journals
Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction - ScienceDirect
In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNA | MaxCyte
CASI Pharmaceuticals | CNCT19
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text
When CAR T cell therapy crashes
Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model: Molecular Therapy - Oncolytics
Is Anti-CD19 CAR T Cell therapy helpful in refractory SLE? The Visual Abract — NephJC
Treatment of aggressive lymphomas with anti-CD19 CAR T cells | Nature Reviews Clinical Oncology
Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus - European Medical Journal
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus | NEJM
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Chimeric antigen receptor car t cell therapy | solution for detection | Miltenyi | Miltenyi Biotec | Deutschland
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
Professor John G Gribben explains why CART-cell therapy has the potential to revolutionise cancer treatment. | Middle East Medical Portal
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges - ScienceDirect
Frontiers | Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant | Leukemia
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
Cells | Free Full-Text | CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE) | BMJ Open
